Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 2/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | GABRP | O00591 | 1/20 | 0.33 |
| ▸ | GABRD | O14764 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123078 | 0.83 | RAD51 (0.50) | RAD51TRPV4ELANE | |
| SCHEMBL11615934 | 0.83 | RAD51 (0.53) | RAD51TRPV4CA1CA2HTT | |
| SCHEMBL123288 | 0.82 | RAD51 (0.49) | RAD51TRPV4CASP3PIK3CDPIK3CA | |
| SCHEMBL3665502 | 0.80 | RAD51 (0.47) | RAD51TRPV4 | |
| SCHEMBL121887 | 0.80 | RAD51 (0.54) | RAD51TRPV4PTGS2CASP3EPAS1 | |
| SCHEMBL232368 | 0.80 | RAD51 (0.54) | RAD51TRPV4PTGS2CASP3EPAS1 | |
| SCHEMBL230720 | 0.79 | RAD51 (0.43) | RAD51ELANE | |
| SCHEMBL230721 | 0.79 | RAD51 (0.43) | RAD51ELANE | |
| SCHEMBL7387829 | 0.79 | RAD51 (0.49) | RAD51TRPV4EPAS1 | |
| SCHEMBL123754 | 0.78 | RAD51 (0.48) | RAD51CA1CA2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604308-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2023-09-13 | — | — | EP | disclosed |
| EP-3539952-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2022-06-22 | — | — | EP | disclosed |
| CN-107253933-B | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | 勃林格殷格翰国际有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3271337-B1 | PROCESS FOR THE PREPARATION OF (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUORMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDIN-5-CARBONITRIL | PH PHARMA CO LTD (KR) | 2021-03-03 | — | — | EP | disclosed |
| EP-3271337-B1 | PROCESS FOR THE PREPARATION OF (4S)-4-[4-CYANO-2-(METHYLSULFONYL)PHENYL]-3,6-DIMETHYL-2-OXO-1-[3-(TRIFLUORMETHYL)PHENYL]-1,2,3,4-TETRAHYDRO PYRIMIDIN-5-CARBONITRIL | PH PHARMA CO LTD (KR) | 2021-03-03 | — | — | EP | disclosed |
| US-10676443-B2 | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | PH PHARMA CO., LTD. (KR) | 2020-06-09 | — | — | US | disclosed |
| US-10676443-B2 | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | PH PHARMA CO., LTD. (KR) | 2020-06-09 | — | — | US | disclosed |
| CN-110981815-A | Process for producing a compound | PH制药有限公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-3604308-A1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2020-02-05 | — | — | EP | disclosed |
| EP-3174862-B1 | SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2234985-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2010078953-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010078953-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2009135599-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135599-A1 | 1,4-DIARYL-PYRIMIDOPYRIDAZINE-2,5-DIONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676443-B2 | Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | CYP2S1, PFAS, DPYD | RAD51 2076/4885TRPV4 1706/4885PTGS2 3260/4885 |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | RAD51 4553/4885TRPV4 1309/4885PTGS2 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.